Matinas BioPharma
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $962 | $0 | $0 |
Gross Profit | -124 | -128 | -243 | |
EBITDA | -1,837 | -1,946 | -4,137 | |
EBIT | -2,074 | -4,381 | ||
Net Income | -5,245 | -1,656 | -8,433 | -4,275 |
Net Change In Cash | 0 | 962 | 0 | 0 |
Free Cash Flow | -2,021 | -2,007 | -3,510 | -3,500 |
Cash | 6,525 | 6,924 | 7,284 | 10,295 |
Basic Shares | 5,086 | 5,086 | 5,086 | 5,037 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $1,096 | $3,188 | $33 |
Gross Profit | -972 | -13,393 | -13,490 | -748 |
EBITDA | -23,359 | -22,825 | -24,234 | -24,455 |
EBIT | -24,331 | -23,766 | -25,132 | -25,236 |
Net Income | -24,251 | -22,942 | -13,015 | -21,173 |
Net Change In Cash | 0 | 1,096 | 3,188 | 33 |
Cost of Revenue | -14,200 | 8,511 | ||
Free Cash Flow | -15,885 | -15,496 | -20,048 | -15,483 |
Cash | 7,284 | 4,787 | 6,830 | 21,029 |
Basic Shares | 4,865 | 4,345 | 4,336 | 4,203 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.03 |
2025-03-31 | -$0.81 |
2024-12-31 | -$0.80 |
2024-09-30 | -$0.85 |
